Company / Operating Cash Flow per Share
Astria Therapeutics, Inc. Operating Cash Flow per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.45
FY2024
5-year range
-$10.62 / -$1.45
FY2020-FY2024
Trend
+36.4%
vs FY2023
Sector context
#133 of 212
Health Care
What the data says
At $-1.45, Astria Therapeutics, Inc.'s operating cash flow per share ranks #133 of 212 in the Health Care sector. Operating Cash Flow per Share has increased for 4 consecutive years, from $-10.62 in FY2020 to $-1.45 in FY2024.
Based on SEC 10-K filings.
-1.45 in FY2024.
Improved from $-2.98 to $-1.45 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#133 of 212 in Health CareTop 63% of 212This company -$1.45 Sector average -$14.72
▼
+90.2% above sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s operating cash flow per share has grown for 4 consecutive years.
- In FY2024, operating cash flow per share increased 36.4% year-over-year.
- Ranks #133 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.45 | +36.4% |
| FY2023 | -$2.27 | +23.7% |
| FY2022 | -$2.98 | +11.9% |
| FY2021 | -$3.38 | +68.2% |
| FY2020 | -$10.62 | -287.2% |
| FY2019 | -$2.74 | +40.9% |
| FY2018 | -$4.64 | +62.5% |
| FY2017 | -$12.38 | -511.4% |
| FY2016 | -$2.02 | +45.4% |
| FY2015 | -$3.70 | +92.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026